---
title: "Anus Laboratories Ltd (532981) — Share Price, Financials & Analysis"
symbol: "532981"
company: "Anus Laboratories Ltd"
canonical: "https://tapetide.com/stocks/532981"
isin: "INE450H01022"
bse_code: "532981"
sector: "Healthcare"
industry: "Pharmaceuticals & Biotechnology"
generated_at: "2026-09-13T19:40:11.794Z"
---

# Anus Laboratories Ltd (532981)

Canonical page: https://tapetide.com/stocks/532981

## Company

- **BSE Code:** 532981
- **ISIN:** INE450H01022
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals & Biotechnology
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2008-06-04
- **Face Value:** ₹1
- **F&O Eligible:** No
- **Website:** anulabs.com

## About

Anu's Laboratories Limited manufactures and supplies drug intermediates and related products for the pharmaceutical industry.

## Latest Price

## Key Insights

### Strengths

- Stock is trading at 0.04 times its book value

### Weaknesses

- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Company has a low return on equity of 8.50% over last 3 years.
- Dividend payout has been low at 3.80% of profits over last 3 years
- Company's cost of borrowing seems high

## Growth Rates

| Metric | 1Y | 3Y | 5Y |
| --- | --- | --- | --- |
| net income growth | -76% | -40% | -23% |
| revenue growth | -2% | 18% | 20% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 255 | 98 | 18 | 82 | 14 | 188 | 8 | 167 | 9 | 32 | 18 | 459 |
| Expenses | 283 | 141 | 53 | 121 | 68 | 230 | 55 | 193 | 64 | 87 | 70 | 429 |
| Operating Profit | -27 | -43 | -35 | -39 | -54 | -42 | -48 | -25 | -55 | -55 | -52 | 30 |
| OPM % | -11 | -44 | -196 | -48 | -379 | -22 | -627 | -15 | -597 | -172 | -299 | 6 |
| Other Income | 38 | 37 | 8 | 82 | 119 | 55 | 45 | 28 | 149 | 107 | 112 | 107 |
| Interest | 3 | 4 | 0 | 0 | 3 | 6 | 7 | 4 | 2 | 4 | 2 | 2 |
| Depreciation | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 6 | 6 | 7 | 6 |
| Profit before tax | 4 | -14 | -30 | 39 | 59 | 3 | -14 | -5 | 87 | 42 | 51 | 129 |
| Tax % | 86 | -69 | -36 | -28 | -22 | -314 | 0 | 336 | 2 | -23 | 6 | 16 |
| Net Profit | 1 | -4 | -19 | 50 | 71 | 13 | -14 | -22 | 85 | 51 | 48 | 109 |
| EPS in Rs | 0.02 | -0.2 | -0.89 | 2.35 | 3.36 | 0.6 | -0.66 | -1.05 | 3.99 | 2.4 | 2.25 | 5.1 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 83 | 104 | 146 | 155 | 198 | 262 | 256 |
| Expenses | 72 | 81 | 111 | 120 | 161 | 216 | 217 |
| Operating Profit | 11 | 23 | 35 | 35 | 36 | 46 | 40 |
| OPM % | 13 | 22 | 24 | 23 | 18 | 18 | 15 |
| Other Income | 1 | 1 | 3 | 0 | 2 | -4 | 0 |
| Interest | 3 | 5 | 8 | 7 | 11 | 17 | 26 |
| Depreciation | 1 | 1 | 1 | 2 | 2 | 4 | 8 |
| Profit before tax | 8 | 18 | 28 | 26 | 26 | 21 | 6 |
| Tax % | 26 | 26 | 36 | 37 | 19 | 37 | 46 |
| Net Profit | 6 | 14 | 18 | 16 | 21 | 13 | 3 |
| EPS in Rs | — | — | — | 0.67 | — | — | 0.14 |
| Dividend Payout % | 14 | 6 | 7 | 12 | 11 | 0 | 0 |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 5 | 8 | 8 | 12 | 24 | 24 | 24 |
| Reserves | 7 | 24 | 43 | 134 | 137 | 138 | 141 |
| Borrowings | 18 | 27 | 41 | 41 | 81 | 97 | 131 |
| Other Liabilities | 17 | 22 | 34 | 38 | 40 | 33 | 38 |
| Total Liabilities | 48 | 81 | 126 | 224 | 282 | 292 | 334 |
| Fixed Assets | 14 | 21 | 22 | 27 | 43 | 94 | 94 |
| CWIP | 0 | 4 | 4 | 17 | 38 | 22 | 35 |
| Investments | 2 | 3 | 3 | 3 | 3 | 0 | 0 |
| Other Assets | 32 | 53 | 97 | 178 | 198 | 176 | 205 |
| Total Assets | 48 | 81 | 126 | 224 | 282 | 292 | 334 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | -5 | 3 | -7 | -42 | 13 | 28 | -10 |
| Cash from Investing Activity | -6 | -13 | -3 | -19 | -40 | -23 | -19 |
| Cash from Financing Activity | 10 | 11 | 9 | 63 | 27 | -4 | 26 |
| Net Cash Flow | 0 | 2 | -1 | 2 | 1 | 2 | -3 |
| Free Cash Flow | -9 | -9 | -10 | -61 | -26 | 6 | -29 |
| CFO/OP | -43 | 14 | -19 | -83 | 60 | 74 | -18 |

### Ratios

| Item | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 22 | 26 | 57 | 146 | 124 | 77 | 119 |
| Inventory Days | 165 | 212 | 231 | 269 | 206 | 140 | 135 |
| Days Payable | 91 | 92 | 63 | 85 | 72 | 13 | 12 |
| Cash Conversion Cycle | 96 | 145 | 225 | 330 | 258 | 204 | 242 |
| Working Capital Days | 72 | 112 | 163 | 317 | 281 | 169 | 206 |
| ROCE % | — | 52 | 48 | 25 | 17 | 17 | 12 |

## Shareholding Pattern

### annual

| Category | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Dec 2025 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 50.83% | 51.56% | 51.53% | 51.52% | 51.46% | 51.33% | 51.28% | 51.17% | 51.14% | 52.41% |
| FIIs | 24.25% | 22.64% | 15.89% | 13.42% | 13.5% | 9.77% | 11.3% | 9.12% | 9.55% | 7.81% |
| DIIs | 2.26% | 3.14% | 6.65% | 13.06% | 14.21% | 18.81% | 19.44% | 22.24% | 20.11% | 22.83% |
| Public | 22.66% | 22.66% | 25.93% | 22% | 20.84% | 20.08% | 17.98% | 17.47% | 19.2% | 16.93% |
| No. of Shareholders | 65420 | 58417 | 57773 | 58187 | 53951 | 68396 | 72865 | 106630 | 115855 | 119560 |

### Quarterly

| Category | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 51.28% | 51.2% | 51.19% | 51.18% | 51.17% | 51.16% | 51.15% | 51.15% | 51.14% | 52.43% | 52.42% | 52.41% |
| FIIs | 11.3% | 11.45% | 11.87% | 8.53% | 9.12% | 9.74% | 9.82% | 9.99% | 9.55% | 8.7% | 8.12% | 7.81% |
| DIIs | 19.44% | 19.86% | 20.18% | 23.18% | 22.24% | 21.26% | 20.91% | 20.7% | 20.11% | 21.82% | 22.45% | 22.83% |
| Public | 17.98% | 17.48% | 16.77% | 17.1% | 17.47% | 17.84% | 18.12% | 18.15% | 19.2% | 17.05% | 17% | 16.93% |
| No. of Shareholders | 72865 | 74132 | 91840 | 97967 | 106630 | 109471 | 111037 | 112386 | 115855 | 118204 | 120808 | 119560 |

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 9 Feb - Mahindra transfers Alembic project to subsidiary; sells 49% to Mitsui; rights issue ~Rs2,303 crore; complete by Mar 31, 2026. | [Execution Of Shareholder''s Agreement And Investment Agreement. 9 Feb - Mahindra transfers Alembic project to subsidiary; sells 49% to Mitsui; rights issue ~Rs2,303 crore; complete by Mar 31, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/84c44e0a-334f-4e36-92c9-f2479c02e11a.pdf) |
| 9 Feb - Mahindra Lifespaces forms JV with Mitsui Fudosan for Mahindra Blossom, ~730 homes in Whitefield, Bengaluru; subject to approvals. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 9 Feb - Mahindra Lifespaces forms JV with Mitsui Fudosan for Mahindra Blossom, ~730 homes in Whitefield, Bengaluru; subject to approvals.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/ff517295-3abc-4ef3-8aa9-d7a7ad92adb9.pdf) |
| 9 Feb - Joint venture with Mitsui Fudosan for Mahindra Blossom (≈730 homes), Bengaluru; first project; announced 09 Feb 2026. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised) 9 Feb - Joint venture with Mitsui Fudosan for Mahindra Blossom (≈730 homes), Bengaluru; first project; announced 09 Feb 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/96973033-34d4-4914-9d3c-b18fe5ee42ac.pdf) |
| 9 Feb - Board approved slump sale of Alembic to MBLDL; 49% stake to Mitsui; rights issue ~Rs230.3 crore. | [Board Meeting Outcome for Outcome Of Board Meeting 9 Feb - Board approved slump sale of Alembic to MBLDL; 49% stake to Mitsui; rights issue ~Rs230.3 crore.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/db936587-8802-4f2f-b49d-ceab26719d6a.pdf) |
| 9 Feb - Board approved slump sale of Alembic project to subsidiary; transfer 49% to Mitsui; consideration ≤Rs100 crore; rights issue subscribed 51:49. | [Board Approved Proposed Sale Of Shares Held In Subsidiary 9 Feb - Board approved slump sale of Alembic project to subsidiary; transfer 49% to Mitsui; consideration ≤Rs100 crore; rights issue subscribed 51:49.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/efbc8925-301d-4c07-82cd-4f4c3f9a3318.pdf) |
| 21 Feb - Newspaper Publication regarding Notice of Postal Ballot and E-voting | [Announcement under Regulation 30 (LODR)-Newspaper Publication 21 Feb - Newspaper Publication regarding Notice of Postal Ballot and E-voting](https://www.bseindia.com/xml-data/corpfiling/AttachHis/5dd5771a-f442-4a12-84d4-da03e9598a95.pdf) |
| 20 Feb - Postal Ballot to approve slump sale of Mahindra Blossom undertaking for up to ₹73.8Cr; NCD investments ₹326Cr; JV with MFA. | [Shareholder Meeting / Postal Ballot-Notice of Postal Ballot 20 Feb - Postal Ballot to approve slump sale of Mahindra Blossom undertaking for up to ₹73.8Cr; NCD investments ₹326Cr; JV with MFA.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3cd28d04-227c-499d-a763-addb43402c14.pdf) |
| 19 Feb - Mahindra Lifespace assigned ESG score 68 by NSE Ratings on 19 Feb 2026 (link provided). | [Announcement under Regulation 30 (LODR)-Credit Rating 19 Feb - Mahindra Lifespace assigned ESG score 68 by NSE Ratings on 19 Feb 2026 (link provided).](https://www.bseindia.com/xml-data/corpfiling/AttachHis/85d6416d-d47c-40c6-86f3-bfe427dd747f.pdf) |
| 19 Feb - Crisil rated proposed INR100 Cr bank limits AA/Stable and proposed INR300 Cr commercial paper A1+, notified Feb 18, 2026. | [Announcement under Regulation 30 (LODR)-Credit Rating 19 Feb - Crisil rated proposed INR100 Cr bank limits AA/Stable and proposed INR300 Cr commercial paper A1+, notified Feb 18, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7dc642ad-8d26-4a5b-a693-3fbde44c909e.pdf) |
| — | [Board Meeting Intimation for Results 17 Mar 2017](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2f56d9c8-124c-46f0-87e7-b4968c4810c2.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Oct 2025 | [Concall - Oct 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/53e41ab3-f830-4bf9-aeba-09c0401ac469.pdf) |
| Oct 2019 | [Concall - Oct 2019](https://www.bseindia.com/xml-data/corpfiling/AttachHis/14e184a2-3c90-4887-a339-b9527fdf9efe.pdf) |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/37021b1b-80d5-4f7c-906d-6a125b2a751f.pdf) |
| Nov 2024 | [Concall - Nov 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7f8b443c-1408-473a-a16b-11dd655d2381.pdf) |
| Nov 2023 | [Concall - Nov 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3ddfd67b-ecef-4841-93e1-d0e75f8a71d6.pdf) |
| Nov 2022 | [Concall - Nov 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/30c3deca-2301-46c4-a7e0-2628316b9266.pdf) |
| May 2025 | [Concall - May 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/26eb0925-1be5-42d8-b863-bf5f4ad393ab.pdf) |
| May 2024 | [Concall - May 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/ed26f0f7-880b-44e2-9604-958258951434.pdf) |
| May 2023 | [Concall - May 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/50390d9b-3773-4254-b537-445177c90731.pdf) |
| May 2022 | [Concall - May 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7a26f24d-d1c0-49a2-8a64-8949d6ed850f.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Financial Year 2011 from nse](https://archives.nseindia.com/annual_reports/AR_MAHLIFE_2010_2011_14072011110509.zip) |
| from bse | [Financial Year 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/019b0c4e-5194-4906-9c35-97f9b961b9c2.pdf) |
| from bse | [Financial Year 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/5c202233-1311-467d-997b-a32132edf386.pdf) |
| from bse | [Financial Year 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d927f4c0-8c40-4692-8ec3-30859257dc80.pdf) |
| from bse | [Financial Year 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/532313/73419532313.pdf) |
| from bse | [Financial Year 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/532313/68728532313.pdf) |
| from bse | [Financial Year 2020 from bse](https://www.bseindia.com/bseplus/AnnualReport/532313/5323130320.pdf) |
| from bse | [Financial Year 2019 from bse](https://www.bseindia.com/bseplus/AnnualReport/532313/5323130319.pdf) |
| from bse | [Financial Year 2018 from bse](https://www.bseindia.com/bseplus/AnnualReport/532313/5323130318.pdf) |
| from bse | [Financial Year 2017 from bse](https://www.bseindia.com/bseplus/AnnualReport/532313/5323130317.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:40:11.794Z.